Evidence map›Paper›PMID 34289123›Full record

ArticleMedical physics2021

Assessment of a diaphragm override strategy for robustly optimized proton therapy planning for esophageal cancer patients.

Sabine Visser, Hendrike Neh, Cássia Oraboni Ribeiro, Erik W Korevaar, Arturs Meijers, Björn Poppe, Nanna M Sijtsema, Stefan Both, Johannes A Langendijk, Christina T Muijs and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Medical physics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Sabine VisserDepartment of Radiation Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Hendrike NehDivision for Medical Radiation Physics, Carl von Ossietzky University Oldenburg, Oldenburg, Germany.
Cássia Oraboni RibeiroDepartment of Radiation Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Erik W KorevaarDepartment of Radiation Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Arturs MeijersDepartment of Radiation Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Björn PoppeDivision for Medical Radiation Physics, Carl von Ossietzky University Oldenburg, Oldenburg, Germany.
Nanna M SijtsemaDepartment of Radiation Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Stefan BothDepartment of Radiation Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Johannes A LangendijkDepartment of Radiation Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Christina T MuijsDepartment of Radiation Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Antje C KnopfDepartment of Radiation Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.

Funding

University Medical Center Groningen NCT03024138
6 · The paper itself

Abstract

purposeTo ensure target coverage in the treatment of esophageal cancer, a density override to the region of diaphragm motion can be applied in the optimization process. Here, we evaluate the benefit of this approach during robust optimization for intensity modulated proton therapy (IMPT) planning. MATERIALS AND

methodsFor 10 esophageal cancer patients, two robustly optimized IMPT plans were created either using (WDO) or not using (NDO) a diaphragm density override of 1.05 g/cm

resultsThe nominal dose distributions were similar for both WDO and NDO plans. However, visual inspection of the Vw

conclusionThe diaphragm override approach did not result in a clinical benefit in terms of planning and interfractional robustness. Therefore, we do not see added value in employing this approach as a default option during robust optimization for IMPT planning in esophageal cancer.

Indexed as

Esophageal NeoplasmsLung NeoplasmsProton TherapyRadiotherapy, Intensity-ModulatedDiaphragmHumansOrgans at RiskRadiotherapy DosageRadiotherapy Planning, Computer-Assisted3D robust optimizationdensity overridediaphragmesophageal cancerintensity modulated proton therapy

Identifiers

PMID34289123
PMCPMC9291176

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.